AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20214068 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Estazolam
Number of subjects: 49
Study 17442905 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 638
Study 16137240 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation plus deep breathing and coughing exercises
Number of subjects: 56
Study 16137240 — intervention group
Group type: COMPARATOR
Intervention: Early mobilisation only
Number of subjects: 56
Study 12404512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) from MS patients with 0.1 mM ITU (specific iNOS inhibitor)
Number of subjects: 0
Study 12404512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) from MS patients with 1 mM L-NMMA (nonisoform specific NOS inhibitor)
Number of subjects: 0
Study 12404512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) from MS patients
Number of subjects: 0
Study 12404512 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) from controls
Number of subjects: 0
Study 9887852 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmural home care programme
Number of subjects: 86
Study 9887852 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 86
Study 7625352 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (HC)
Number of subjects: 20
Study 7625352 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet combined with exercise training (HC-EX)
Number of subjects: 20
Study 2122855 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PTCA (24‐72 hours)
Number of subjects: 50
Study 2122855 — intervention group
Group type: COMPARATOR
Intervention: Delayed PTCA (8‐10 days)
Number of subjects: 50
Study 354826 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alpha-methyldopa hydrazine
Number of subjects: 8
Study 354826 — intervention group
Group type: COMPARATOR
Intervention: alpha-methyldopa
Number of subjects: 8
Study 31340316 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength program with TheraBands® for 12 weeks, with two weekly sessions
Number of subjects: 26
Study 31340316 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 26
Study 31340316 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength program with TheraBands®
Number of subjects: 26
Study 28899491 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and Lycopene supplementation (Group A)
Number of subjects: 209
Study 28899491 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 209
Study 25981709 — intervention group
Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC) with target inflation pressures of 70 mmHg for 1 h
Number of subjects: 20
Study 25981709 — intervention group
Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC)
Number of subjects: 20
Study 22981376 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (2 hours weekly for six months)
Number of subjects: 118
Study 22981376 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy (control for patients)
Number of subjects: 118
Study 22981376 — intervention group
Group type: COMPARATOR
Intervention: Life-as-usual (control for healthy controls)
Number of subjects: 118
Study 21232801 — intervention group
Group type: EXPERIMENTAL
Intervention: IVTA plus laser
Number of subjects: 84
Study 21232801 — intervention group
Group type: COMPARATOR
Intervention: Laser only
Number of subjects: 84
Study 18070232 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (200 U)
Number of subjects: 32
Study 18070232 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 32
Study 17058778 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 0
Study 12943436 — intervention group
Group type: EXPERIMENTAL
Intervention: Active infant orthopedic treatment with Latham dentomaxillary alignment (DMA) appliance inserted at 5 to 6 weeks of age.
Number of subjects: 40
Study 12943436 — intervention group
Group type: COMPARATOR
Intervention: No active infant orthopedic treatment (nonorthopedic group).
Number of subjects: 40
Study 11711509 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg per day)
Number of subjects: 0
Study 11711509 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg per day)
Number of subjects: 0
Study 11711509 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amiloride and spironolactone
Number of subjects: 0
Study 11711509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9164679 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary medical therapy (PMT)
Number of subjects: 147
Study 9164679 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemoendocrine therapy
Number of subjects: 147
Study 9164679 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement by enzyme immunoassay (EIA)
Number of subjects: 147
Study 8047746 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate information time for monitoring treatment effects
Number of subjects: 0
Study 3310870 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐2a interferon at 30 X 10(6) IU/ml
Number of subjects: 94
Study 3310870 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐2a interferon at 10 X 10(6) IU/ml
Number of subjects: 94
Study 3310870 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 94
Study 2100737 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aqueous extract (Group A)
Number of subjects: 60
Study 2100737 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg standardized extract (Group C)
Number of subjects: 60
Study 2100737 — intervention group
Group type: COMPARATOR
Intervention: Lactose control (Group B)
Number of subjects: 60
Study 775694 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ambulation and discharge after cataract surgery
Number of subjects: 100
Study 31703670 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmural Trauma Care Model (TTCM)
Number of subjects: 83
Study 31703670 — intervention group
Group type: COMPARATOR
Intervention: Regular care (Control)
Number of subjects: 83
Study 28252190 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D pearls
Number of subjects: 50
Study 28252190 — intervention group
Group type: COMPARATOR
Intervention: Placebo pearls
Number of subjects: 50
Study 25543971 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day (or 5 mg/kg/day)
Number of subjects: 38
Study 25543971 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 38
Study 25543971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 23953594 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg/day of vitamin K1
Number of subjects: 50
Study 23953594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21430088 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 (0.8 pmol · kg(‐1) · min(‐1))
Number of subjects: 9
Study 19283541 — intervention group
Group type: EXPERIMENTAL
Intervention: Public service announcements (PSAs) with celebrity character appeal
Number of subjects: 0
Study 19283541 — intervention group
Group type: EXPERIMENTAL
Intervention: Public service announcements (PSAs) with noncelebrity character appeal
Number of subjects: 0
Study 19283541 — intervention group
Group type: EXPERIMENTAL
Intervention: High-involvement message content
Number of subjects: 0
Study 19283541 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-involvement message content
Number of subjects: 0
Study 17374063 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 8
Study 17374063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet radiation (UVB)
Number of subjects: 8
Study 17374063 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical high-potency corticosteroid before UVB exposure
Number of subjects: 8
Study 17374063 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 8
Study 12638566 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1 mg x kg(‐1)
Number of subjects: 20
Study 12638566 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg x kg(‐1)
Number of subjects: 20
Study 11228063 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 252
Study 11228063 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 252
Study 8896779 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 20
Study 8896779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1796130 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg infusion
Number of subjects: 29
Study 1796130 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (control)
Number of subjects: 29
Study 1796130 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptics (on treatment)
Number of subjects: 29
Study 1796130 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptics (off treatment)
Number of subjects: 29
Study 6366804 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol
Number of subjects: 222
Study 6366804 — intervention group
Group type: COMPARATOR
Intervention: Long-acting propranolol
Number of subjects: 222
Study 31825525 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal paracentesis and intraperitoneal infusion of catumaxomab
Number of subjects: 245
Study 31825525 — intervention group
Group type: COMPARATOR
Intervention: Abdominal paracentesis alone
Number of subjects: 245
Study 31825525 — intervention group
Group type: EXPERIMENTAL
Intervention: Catumaxomab infusion
Number of subjects: 245
Study 28650782 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Lactobacillus acidophilus ATCC 4356 and Bifidobacterium bifidum ATCC 29521 (200 g daily)
Number of subjects: 50
Study 28650782 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol-containing chewing gums (two gums three times daily after each meal; total xylitol content: 5.58 g daily)
Number of subjects: 50
Study 25886945 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-relevant Facebook and text message intervention (FI)
Number of subjects: 29
Study 25886945 — intervention group
Group type: COMPARATOR
Intervention: Non-culturally tailored print-based intervention (PI)
Number of subjects: 29
Study 23296812 — intervention group
Group type: COMPARATOR
Intervention: COLD (15°C)
Number of subjects: 198
Study 23296812 — intervention group
Group type: COMPARATOR
Intervention: NEUTRAL (21°C)
Number of subjects: 198
Study 23296812 — intervention group
Group type: EXPERIMENTAL
Intervention: HOT (30°C)
Number of subjects: 198
Study 23296812 — intervention group
Group type: COMPARATOR
Intervention: DIM (11 lx)
Number of subjects: 198
Study 23296812 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIGHT (433 lx)
Number of subjects: 198
Study 23296812 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature (15°C to 30°C)
Number of subjects: 198
Study 21596326 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 2797
Study 21596326 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 2797
Study 19635898 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 200 mg weekly for 6 months
Number of subjects: 120
Study 19635898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16943671 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation plus TACE and PVC (group C)
Number of subjects: 131
Study 16943671 — intervention group
Group type: COMPARATOR
Intervention: Operation only (group A)
Number of subjects: 131
Study 16943671 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation plus TACE (group B)
Number of subjects: 131
Study 15235332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 15
Study 15235332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate
Number of subjects: 15
Study 15235332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate
Number of subjects: 15
Study 15235332 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (placebo)
Number of subjects: 15
Study 10847537 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable polylactic acid (PLA) barrier
Number of subjects: 19
Study 10847537 — intervention group
Group type: COMPARATOR
Intervention: Non-resorbable polytetrafluoroethylene (e-PTFE) barrier
Number of subjects: 19
Study 10170460 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) 5 micrograms/kg/day
Number of subjects: 154
Study 10170460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 10170460 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 154
Study 1585296 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg temazepam
Number of subjects: 8
Study 1585296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4055206 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner counselling and follow-up in a smoking cessation programme
Number of subjects: 0
Study 4055206 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 4055206 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at first three visits
Number of subjects: 0
Study 4055206 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing smokers
Number of subjects: 0
Study 4055206 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in stated cigarette consumption
Number of subjects: 0
Study 31326055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy application
Number of subjects: 0
Study 31326055 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30266270 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus plantarum P8 (10 log CFU daily)
Number of subjects: 103
Study 30266270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 28470492 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (30 mL for 90 days)
Number of subjects: 79
Study 28470492 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (30 mL for 90 days)
Number of subjects: 79
Study 28470492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil (30 mL for 90 days)
Number of subjects: 79
Study 25423324 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor training
Number of subjects: 23
Study 25423324 — intervention group
Group type: COMPARATOR
Intervention: Indoor training
Number of subjects: 23
Study 23756301 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray mineral trioxide aggregate (GMTA)
Number of subjects: 152
Study 23756301 — intervention group
Group type: COMPARATOR
Intervention: Diluted formocresol (DFC)
Number of subjects: 152
Study 20856256 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction only (CR)
Number of subjects: 61
Study 20856256 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction + moderate-intensity exercise (CR+moderate)
Number of subjects: 61
Study 20856256 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction + vigorous-intensity exercise (CR+vigorous)
Number of subjects: 61
Study 20856256 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (CR, CR+moderate, CR+vigorous)
Number of subjects: 61
Study 18300929 — intervention group
Group type: EXPERIMENTAL
Intervention: NDT-based trunk activation protocol
Number of subjects: 0
Study 18300929 — intervention group
Group type: COMPARATOR
Intervention: Parent-infant interaction and play protocol (Control)
Number of subjects: 0
Study 16931694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (n = 25)
Number of subjects: 50
Study 16931694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (n = 25)
Number of subjects: 50
Study 12917744 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g caffeine
Number of subjects: 30
Study 10632642 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 2 mg b.d.
Number of subjects: 462
Study 10632642 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 0.5 mg b.d.
Number of subjects: 462
Study 10632642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 9443520 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg, p.o.
Number of subjects: 0
Study 9443520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg, p.o.
Number of subjects: 0
Study 9443520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8440100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent machine hemofiltration (4 hrs)
Number of subjects: 32
Study 8440100 — intervention group
Group type: COMPARATOR
Intervention: Continuous modes of renal replacement therapy (CAVH/CAVHD)
Number of subjects: 32
Study 3734264 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation with heparin
Number of subjects: 90
Study 3734264 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant therapy
Number of subjects: 90
Study 27650406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 20‐70 mg/day, n=25
Number of subjects: 50
Study 27650406 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=25
Number of subjects: 50
Study 24018777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment at 1-month interval
Number of subjects: 13
Study 24018777 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO2 laser treatment at 3-month interval
Number of subjects: 13
Study 24018777 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment intervals (1-month and 3-month)
Number of subjects: 13
Study 23169469 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic PEG for early enteral feeding
Number of subjects: 134
Study 23169469 — intervention group
Group type: COMPARATOR
Intervention: Nutritional care according to clinical praxis
Number of subjects: 134
Study 20484640 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) delivered at different times before grasping the object.
Number of subjects: 0
Study 20484640 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cues about object weight available during grasping.
Number of subjects: 0
Study 20484640 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticospinal excitability (CSE) changes assessed by TMS.
Number of subjects: 0
Study 18679142 — intervention group
Group type: EXPERIMENTAL
Intervention: Calfactant
Number of subjects: 52
Study 18679142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 16809072 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as allocated (specific intervention details not available)
Number of subjects: 402
Study 16809072 — intervention group
Group type: EXPERIMENTAL
Intervention: Video observations
Number of subjects: 402
Study 12954305 — intervention group
Group type: EXPERIMENTAL
Intervention: HSM PMMA IOL
Number of subjects: 180
Study 12954305 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 180
Study 12954305 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IOL
Number of subjects: 180
Study 10996870 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen IR (isoniazid 300 mg daily and rifampin 600 mg daily)
Number of subjects: 133
Study 10996870 — intervention group
Group type: COMPARATOR
Intervention: Regimen I (isoniazid 300 mg daily for 12 months)
Number of subjects: 133
Study 10996870 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen IR
Number of subjects: 133
Study 10996870 — intervention group
Group type: COMPARATOR
Intervention: Regimen I
Number of subjects: 133
Study 10996870 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 133
Study 7706541 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Paradent (triclosan/copolymer dentifrice)
Number of subjects: 123
Study 7706541 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepsodent Gum Health (triclosan/zinc citrate dentifrice)
Number of subjects: 123
Study 7706541 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentosal Friskt Tandkött (triclosan/pyrophosphate dentifrice)
Number of subjects: 123
Study 7706541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium monofluorophosphate dentifrice)
Number of subjects: 123
Study 7706541 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Paradent
Number of subjects: 123
Study 7706541 — intervention group
Group type: COMPARATOR
Intervention: Dentosal, Pepsodent, and placebo groups
Number of subjects: 123
Study 2693621 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPN) 125mg
Number of subjects: 19
Study 2693621 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (MCP) 20mg
Number of subjects: 19
Study 2693621 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPN)
Number of subjects: 19
Study 2693621 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MPN) and Metoclopramide (MCP)
Number of subjects: 19
Study 367794 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 367794 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 30865775 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD)
Number of subjects: 100
Study 30865775 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 100
Study 30865775 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 100
Study 31303261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 67
Study 31303261 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 28535785 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted medication therapy management (MTM) intervention
Number of subjects: 50
Study 28535785 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50